# Y-mAbs Therapeutics Inc. (YMAB)

Source: https://www.quantisnow.com/company/YMAB
Generated: 2026-11-16T20:26:06.514Z

- Ticker: YMAB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- Website: ymabs.com

## About

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

## Latest YMAB news and filings

- 2025-09-26 12:30 UTC [SEC Form 15-12G filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-y-mabs-therapeutics-inc-6212654)
- 2025-09-19 10:00 UTC [SEC Form 4] [Director Hamill Laura returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-hamill-laura-returned-25080-shares-to-the-company-closing-6206221)
- 2025-09-19 01:39 UTC [SEC Form 4] [Director Wg Biotech Aps closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-wg-biotech-aps-closing-all-direct-ownership-in-the-6206170)
- 2025-09-19 01:29 UTC [SEC Form 4] [SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J](https://www.quantisnow.com/insight/sec-form-4-filed-by-svp-danyelza-bus-unit-head-6206166)
- 2025-09-19 01:27 UTC [SEC Form 4] [Director Gill David N returned $50,095 worth of shares to the company (30,905 units at $1.62), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-gill-david-n-returned-50095-worth-of-shares-to-6206165)
- 2025-09-19 01:24 UTC [SEC Form 4] [Director Tyagi Ashu returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-tyagi-ashu-returned-25080-shares-to-the-company-closing-6206163)
- 2025-09-19 01:12 UTC [SEC Form 4] [CHIEF BUSINESS OFFICER Gad Thomas returned 60,235 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-officer-gad-thomas-returned-60235-shares-to-the-6206156)
- 2025-09-19 01:09 UTC [SEC Form 4] [EVP, CFO and Treasurer Pfreundschuh Peter P. returned 77,800 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/evp-cfo-and-treasurer-pfreundschuh-peter-p-returned-77800-shares-6206153)
- 2025-09-19 01:08 UTC [SEC Form 4] [PRESIDENT & CEO Rossi Michael J returned 129,101 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-rossi-michael-j-returned-129101-shares-to-the-6206152)
- 2025-09-19 01:06 UTC [SEC Form 4] [SVP & CHIEF OPERATING OFFICER Wilms Joris returned 39,301 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/svp-chief-operating-officer-wilms-joris-returned-39301-shares-to-6206150)
- 2025-09-19 01:03 UTC [SEC Form 4] [Director Wedell-Wedellsborg Johan returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-wedell-wedellsborg-johan-returned-25080-shares-to-the-company-closing-6206148)
- 2025-09-19 01:01 UTC [SEC Form 4] [SVP, General Counsel & Secry Larocca John returned 21,500 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/svp-general-counsel-secry-larocca-john-returned-21500-shares-to-6206147)
- 2025-09-19 00:59 UTC [SEC Form 4] [Director Healy James returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-healy-james-returned-25080-shares-to-the-company-closing-6206145)
- 2025-09-17 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-y-mabs-therapeutics-inc-6203219)
- 2025-09-16 13:10 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-y-mabs-therapeutics-inc-6202077)
- 2025-09-16 13:07 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-y-mabs-therapeutics-inc-6202071)
- 2025-09-16 13:06 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-y-mabs-therapeutics-inc-6202070)
- 2025-09-16 13:04 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-y-mabs-therapeutics-inc-6202068)
- 2025-09-16 13:03 UTC [SEC Form POS AM filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-y-mabs-therapeutics-inc-6202066)
- 2025-09-16 12:59 UTC [SEC Form 8-K] [Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/y-mabs-therapeutics-inc-filed-sec-form-8-k-completion-of-acquisition-6201995)
- 2025-09-16 12:56 UTC [SEC Form 25-NSE filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-y-mabs-therapeutics-inc-6201992)
- 2025-09-16 12:56 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-y-mabs-therapeutics-inc-6201991)
- 2025-09-02 12:30 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-y-mabs-therapeutics-inc-6185076)
- 2025-08-18 13:24 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-y-mabs-therapeutics-inc-6169631)
- 2025-08-15 20:28 UTC [SEC Form SCHEDULE 13G filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-y-mabs-therapeutics-inc-6168511)
- 2025-08-12 20:16 UTC [SEC Form SCHEDULE 13G filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-y-mabs-therapeutics-inc-6160803)
- 2025-08-08 11:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-y-mabs-therapeutics-inc-6155394)
- 2025-08-08 11:18 UTC [SEC Form 8-K] [Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/y-mabs-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6155381)
- 2025-08-08 10:35 UTC [Earnings Date] [Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments](https://www.quantisnow.com/insight/y-mabs-reports-second-quarter-2025-financial-results-and-recent-corporate-6155300)
- 2025-08-07 11:30 UTC [Earnings Date] [Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025](https://www.quantisnow.com/insight/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-6152281)
- 2025-08-06 21:25 UTC [SEC Form SC14D9C filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-y-mabs-therapeutics-inc-6151536)
- 2025-08-05 21:09 UTC [SEC Form SC14D9C filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc14d9c-filed-by-y-mabs-therapeutics-inc-6148218)
- 2025-08-05 13:30 UTC [SEC Form 8-K] [Y-mAbs Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/y-mabs-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6146700)
- 2025-08-05 12:30 UTC [SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics](https://www.quantisnow.com/insight/serb-pharmaceuticals-agrees-to-acquire-y-mabs-therapeutics-6146489)
- 2025-07-15 20:15 UTC [SEC Form 8-K] [SEC Form 8-K filed by Y-mAbs Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-y-mabs-therapeutics-inc-6120760)
- 2025-07-02 20:20 UTC [SEC Form 4] [Director Tyagi Ashu was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)](https://www.quantisnow.com/insight/director-tyagi-ashu-was-granted-25080-shares-increasing-direct-ownership-6108546)
- 2025-07-02 20:20 UTC [SEC Form 4] [Director Hamill Laura was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)](https://www.quantisnow.com/insight/director-hamill-laura-was-granted-25080-shares-increasing-direct-ownership-6108545)
- 2025-07-02 20:20 UTC [SEC Form 4] [Director Healy James was granted 25,080 shares, increasing direct ownership by 79% to 56,683 units (SEC Form 4)](https://www.quantisnow.com/insight/director-healy-james-was-granted-25080-shares-increasing-direct-ownership-6108541)
- 2025-07-02 20:20 UTC [SEC Form 4] [Director Wedell-Wedellsborg Johan was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)](https://www.quantisnow.com/insight/director-wedell-wedellsborg-johan-was-granted-25080-shares-increasing-direct-ownership-6108540)
- 2025-07-02 20:20 UTC [SEC Form 4] [Director Gill David N was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)](https://www.quantisnow.com/insight/director-gill-david-n-was-granted-25080-shares-increasing-direct-6108533)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/YMAB
- Earnings history: https://www.quantisnow.com/earnings/YMAB
- Dividend history: https://www.quantisnow.com/dividends/YMAB
- Insider transactions: https://www.quantisnow.com/insiders/YMAB
- Options chain: https://www.quantisnow.com/options/YMAB
- SEC 8-K filings only: https://www.quantisnow.com/company/YMAB/8-k
- RSS and alerts for YMAB: https://www.quantisnow.com/docs/rss-feeds.md
